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“Solidarity Trial”: A Feeling of Trust Towards 
COVID-19 Treatments
 Corona Virus Disease (COVID-19) drugs are 
not being developed at the pace in which the disease 
is spreading throughout the world. WHO and its 
partners have announced the worldwide clinical trial 
on 18th March 2020, known as “Solidarity Trial” 
for greater co-ordination of developments of drugs.
[1]“Solidarity Trialis an international clinical trial 
to help find an effective treatment for COVID-19”.[1, 
2] The trial is randomized, open-label and adaptive. 
This trial will analyze four treatment options 
against standard of care, after recruiting patients 
from various countries, and then will approach to 
their relative effectiveness against the disease. The 
aim of this trial is to rapidly explore if any of the 
administered drugs will slow progression of disease 
or improve survival.[2]
 The rationale of conducting “Solidarity 
Trial” is to reduce time taken by the trials. 
Randomized clinical trials generally take years to 
conduct, while, “Solidarity Trial” will reduce the 
duration by 80%.[2] By enrolling patients from 
around the world, this trial might be able to provide 
result more rapidly than multiple small trials. 
Moreover, those small multiple trials will not be 
able to gather solid evidence required to determine 
the relative effectiveness of given unproven drugs.
[2] Besides this, with involvement of multiple 
countries, the cost of trial will also reduce. Already, 
100 countries including Norway, Canada, Spain, 
Argentina, Thailand, South Africa, India, Indonesia, 
Switzerland and others have committed to join this 
trial. Norway is the first country to contribute its 
first patient for this important trial.[2] This trial will 
provide simplified procedure to enable hospitals to 
participate without any paperwork. The countries 
with least infrastructure can follow a main protocol, 
while those with better facility will launch “daughter 
trials” that will gather added data.[2,3]
 Four treatment options are selected for this 
trial on the basis of evidence gathered from animal 
studies, clinical studies and laboratory results. They 
are Remdesivir, Lopinavir with Ritonavir, Lopinavir 
with Ritonavir + Interferon beta-1a and Chloroquine 
or Hydroxychloroquine.[2,3] Remdesivir, acts by 
inhibiting RNA-dependent RNA polymerase and 
stops viral replication, has provided encouraging 
outcome in Middle East Respiratory Syndrome 
(MERS) and Severe Acute Respiratory Syndrome 
(SARS).[2,3] Lopinavir /Ritonavir, approved for 
treatment of HIV, are protease inhibitors. They 
block the aspartic protease enzyme that breaks down 
proteins into small pieces  needed for viral replication.
[3] These drugs were tried in China for treatment of 
COVID-19.[4] But, there was no significant clinical 
improvement and reduction in mortality among 
patients. However, there was reduction in median 
time to clinical improvement by one day comparing 
to standard-care group.[4] Interferon beta-1a is a 
class of protein called cytokines that are produced 
by host cells in response to virus. Then, they signal 
other cells around them to enhance anti-virus 
defense mechanism.[3] It has shown some effective 
results against COVID-19 in combination with 
Lopinavir/Ritonavir.[2,3] Furthermore, Chloroquine 
or hydroxychloroquine are believed to interfere with 
fusion of virus with host cell by increasing pH of 
viral endosome or to allow zinc influx to viral cell 
that inhibits RNA-dependent RNA polymerase.[3] 
They have shown possible beneficial effect against 
pneumonia caused by COVID-19 in small studies 
conducted in China and France.[2,3]
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 Eligible patients for this trial are adults (age 
≥ 18years) with confirmed diagnosis of COVID-19 
recently or already admitted to participant hospital.
[2] Patients with any contraindication to the study 
treatments will be excluded from trial. The patients 
are asked to sign written consent which explains that 
they understand all the possible risks and beneficial 
effects of this trial. .[2] There will be a medical team 
for each patient responsible to monitor if any of 
the study treatment would be definitely unsuitable 
to the patient. The severity of disease is assessed 
by recording clinical presentations like difficulty in 
breathing, patient on oxygen, patient on ventilator, 
and radiography of chest showing bilateral lung 
abnormalities. The underlying medical conditions 
are also recorded like chronic lung disease, chronic 
heart disease, chronic liver disease, chronic renal 
disease, tuberculosis and HIV.[2] Then, the patients 
are randomly allocated to treatment options. This 
may include local standard of treatment only OR 
local standard of treatment PLUS one of Remdesivir, 
Chloroquine or Hydroxychloroquine, Lopinavir with 
Ritonavir, Lopinavir with Ritonavir PLUS Interferon 
beta-1a.[2.3] This random allocation of treatment 
options is done by computer, not any medical staff. 
The critical information of trial is only collected 
at randomization stage and at the time patient is 
discharged or dead. This information includes 
which drugs were given, duration of therapy, date of 
discharges, date of death and cause of death.[2] This 
entire trial is monitored by Global Data and Safety 
Monitoring Committee, an independent group of 
experts.[2]
 This clinical trial has brought the world to 
one stage for common goal related to health issue. 
The world may believe that this trial will soon bring 
good and positive result of treatment options for 
COVID-19 with the support of multiple countries 
under umbrella of WHO. Additionally, this trial will 
also create important basis for conducting new trials 
collaboratively if any new pandemics will occur 
unfortunately in the future.
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